Compare NCEL & CRMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCEL | CRMT |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | Switzerland | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 19.7M |
| IPO Year | N/A | 2026 |
| Metric | NCEL | CRMT |
|---|---|---|
| Price | $3.49 | $3.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 30.5K | ★ 1.1M |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 147.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,390,932,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $1.38 |
| 52 Week High | $5.12 | $62.55 |
| Indicator | NCEL | CRMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 28.94 |
| Support Level | $2.95 | $1.38 |
| Resistance Level | $3.62 | $13.68 |
| Average True Range (ATR) | 0.24 | 1.15 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 100.00 | 23.17 |
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.